These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38958627)

  • 41. Concise Review: Towards the Clinical Translation of Induced Pluripotent Stem Cell-Derived Blood Cells-Ready for Take-Off.
    Haake K; Ackermann M; Lachmann N
    Stem Cells Transl Med; 2019 Apr; 8(4):332-339. PubMed ID: 30585439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pluripotent Stem Cells in Clinical Cell Transplantation: Focusing on Induced Pluripotent Stem Cell-Derived RPE Cell Therapy in Age-Related Macular Degeneration.
    Yang YP; Hsiao YJ; Chang KJ; Foustine S; Ko YL; Tsai YC; Tai HY; Ko YC; Chiou SH; Lin TC; Chen SJ; Chien Y; Hwang DK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.
    Cerneckis J; Cai H; Shi Y
    Signal Transduct Target Ther; 2024 Apr; 9(1):112. PubMed ID: 38670977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induced pluripotent stem cell technology: a decade of progress.
    Shi Y; Inoue H; Wu JC; Yamanaka S
    Nat Rev Drug Discov; 2017 Feb; 16(2):115-130. PubMed ID: 27980341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges.
    Farboud SP; Fathi E; Valipour B; Farahzadi R
    J Transl Med; 2024 Aug; 22(1):783. PubMed ID: 39175068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation.
    Paes BCMF; Moço PD; Pereira CG; Porto GS; de Sousa Russo EM; Reis LCJ; Covas DT; Picanço-Castro V
    Cell Biol Toxicol; 2017 Jun; 33(3):233-250. PubMed ID: 28039590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation.
    Netsrithong R; Garcia-Perez L; Themeli M
    Front Immunol; 2023; 14():1325209. PubMed ID: 38283344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transplantable liver organoids made from only three ingredients.
    Willenbring H; Soto-Gutierrez A
    Cell Stem Cell; 2013 Aug; 13(2):139-40. PubMed ID: 23910079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overcoming barriers to the clinical utilization of iPSCs: reprogramming efficiency, safety and quality.
    Cao S; Loh K; Pei Y; Zhang W; Han J
    Protein Cell; 2012 Nov; 3(11):834-45. PubMed ID: 23073833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
    Flahou C; Morishima T; Takizawa H; Sugimoto N
    Front Immunol; 2021; 12():662360. PubMed ID: 33897711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent technological updates and clinical applications of induced pluripotent stem cells.
    Diecke S; Jung SM; Lee J; Ju JH
    Korean J Intern Med; 2014 Sep; 29(5):547-57. PubMed ID: 25228828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induced pluripotent stem cells and their implication for regenerative medicine.
    Csobonyeiova M; Polak S; Koller J; Danisovic L
    Cell Tissue Bank; 2015 Jun; 16(2):171-80. PubMed ID: 25037593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is Human-induced Pluripotent Stem Cell the Best Optimal?
    Wang F; Kong J; Cui YY; Liu P; Wen JY
    Chin Med J (Engl); 2018 Apr; 131(7):852-856. PubMed ID: 29578130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progress and promise towards safe induced pluripotent stem cells for therapy.
    Seifinejad A; Tabebordbar M; Baharvand H; Boyer LA; Salekdeh GH
    Stem Cell Rev Rep; 2010 Jun; 6(2):297-306. PubMed ID: 20180049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of induced pluripotent stem cells in domestic animals: a narrative review.
    Scarfone RA; Pena SM; Russell KA; Betts DH; Koch TG
    BMC Vet Res; 2020 Dec; 16(1):477. PubMed ID: 33292200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.
    Mohite P; Puri A; Dave R; Budar A; Munde S; Ghosh SB; Alqahtani T; Shmrany HA; Kumer A; Dhara B
    Int J Surg; 2024 Oct; 110(10):6432-6455. PubMed ID: 38963728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An HLA-homozygous haplobank resource to promote safer cell therapies.
    Stacey GN
    Cell Stem Cell; 2023 Feb; 30(2):118-119. PubMed ID: 36736287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical studies for induced pluripotent stem cell-based therapeutics.
    Harding J; Mirochnitchenko O
    J Biol Chem; 2014 Feb; 289(8):4585-93. PubMed ID: 24362021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells.
    Itoh M; Kiuru M; Cairo MS; Christiano AM
    Proc Natl Acad Sci U S A; 2011 May; 108(21):8797-802. PubMed ID: 21555586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.